IP Library Granted Patent US 10,982,016
Granted Patent B2
US 10,982,016 · App. 16/781,264 · Granted Apr 20, 2021

Method for manufacturing a shaped cross-linked hyaluronic acid product

Inventors: Morgan Karlsson (Knivsta, SE); Anne Helander Kenne (Marsta, SE); Åke Öhrlund (Uppsala, SE)
Assignee: GALDERMA HOLDING SA
C08B37/0072A61K8/042A61K8/735A61K9/0024A61K31/728A61Q19/00A61Q19/08D01F9/00A61K2800/91
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,982,016
App. No.
16/781,264
Granted
Apr 20, 2021
Kind
B2
Abstract

A method for manufacturing a shaped cross-linked hyaluronic acid product including the step of subjecting a non-cross-linked precipitated hyaluronic acid substrate in a desired shape to a single cross-linking reaction in a liquid medium having a pH of 11.5 or higher and including one or more polyfunctional cross-linking agent(s) and an amount of one or more organic solvent(s) giving precipitating conditions for hyaluronic acid, under suitable conditions to obtain a precipitated, shaped cross-linked hyaluronic acid product having a degree of modification of 1-40 cross-linking agent units per 1000 disaccharide units.

Claims (25)

1. A string product with a length to width ratio of at least 10:1, comprising multiple layers of hyaluronic acid (HA) and an external layer of cross-linked HA.

2. The product according to claim 1 , wherein the string comprises an internal layer of non-cross-linked HA.

3. The product according to claim 1 , wherein the string comprises an internal layer of cross-linked HA that exhibits a different degree of modification than the external layer.

4. The product according to claim 3 , wherein the internal layer of cross-linked HA exhibits a lower degree of modification than the external layer.

5. The product according to claim 1 , wherein one or more of the multiple layers is formed by extrusion.

6. The product according to claim 1 , wherein the string has a length to width ratio of at least 100:1.

7. The product according to claim 1 , wherein the string has a length to width ratio of at least 25000:1.

8. The product according to claim 1 , wherein the string has a diameter less than 1 mm.

9. The product according to claim 1 , wherein the string has a diameter from 0.3 to 0.5 mm.

10. The product according to claim 1 , wherein the string has a diameter from 0.5 to 1 mm.

11. The product according to claim 1 , wherein the HA is of non-animal origin.

12. The product according to claim 1 , wherein the string is woven together to form a net.

13. The product according to claim 12 , wherein the net is greater than 5 mm in at least one dimension.

14. The product according to claim 1 , wherein the string is dry.

15. The product according to claim 1 , wherein the string is partially swollen.

16. The product according to claim 1 , further comprising one or more drugs.

17. The product according to claim 16 , wherein the one or more drugs are selected from the group consisting of: an anesthetic, an anti-inflammatory agent, an antibiotic, and a growth factor.

18. The product according to claim 1 , further comprising one or more proteins.

19. The product according to claim 1 , further comprising one or more cells.

20. The product according to claim 19 , wherein the one or more cells are human cells.

21. A composition comprising a string product with a length to width ratio of at least 10:1, comprising multiple layers of hyaluronic acid (HA) and an external layer of cross-linked HA.

22. The composition according to claim 21 , wherein the composition is sterile.

23. The composition according to claim 21 , further comprising a buffering agent.

24. A composition comprising a plurality of string products with a length to width ratio of at least 10:1, wherein the string products comprise multiple layers of hyaluronic acid (HA) and an external layer of cross-linked HA.

25. The composition according to claim 24 , wherein at least 50% of the string products have a length to width ratio of at least 20:1.

Assignments (4)
CHANGE OF ADDRESS Recorded Jun 28, 2022
From: GALDERMA HOLDING SA
To: GALDERMA HOLDING SA
Reel/Frame 060541/0374 →
CHANGE OF NAME Recorded Sep 28, 2021
From: NESTLÉ SKIN HEALTH S.A.
To: GALDERMA HOLDING SA
Reel/Frame 057630/0741 →
ASSET TRANSFER AGREEMENT Recorded Mar 15, 2021
From: GALDERMA SA
To: NESTLÉ SKIN HEALTH S.A.
Reel/Frame 055598/0667 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2020
From: KARLSSON, MORGAN; KENNE, ANNE HELANDER; OHRLUND, AKE
To: GALDERMA S.A.
Reel/Frame 052495/0324 →